Home » Topics » Science » New compound

New compound
RSS

VRN-071961: a potent EGFR kinase inhibitor active in Ex20Ins EGFR mutation-driven NSCLC

Nov. 5, 2019

KYM-003, potent and selective STAT3 degrader with strong antitumor activity in vivo

Nov. 5, 2019

Development of novel PRKACA inhibitors for the treatment of fibrolamellar carcinoma

Nov. 5, 2019

RP-7214: a novel DHODH inhibitor with oral activity in preclinical AML models

Nov. 4, 2019

BGS-2019: a new GMPS inhibitor for the treatment of lupus nephritis

Nov. 4, 2019

NTS2-selective compounds with promising activity in preclinical models of pain

Nov. 4, 2019

Preclinical evaluation of highly potent caspase-cleavable docetaxel prodrug, MPD-03

Oct. 31, 2019

New compounds block Tat binding to human DAT for HAND treatment

Oct. 31, 2019

Novel class I HDAC inhibitor R8 demonstrates efficacy both in vitro and in vivo

Oct. 28, 2019

Preclinical results presented of a gene therapy for the treatment of retinitis pigmentosa

Oct. 28, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...